Clinical Cancer Research: 20 (10)

Highlights

Highlights

Highlights of This Issue

Clin Cancer Res May 15 2014 20 (10) 2503-2503;

CCR Translations

CCR Translations

Minimal Residual Disease in Breast Cancer: In Blood Veritas

Giulia Siravegna and Alberto Bardelli

Clin Cancer Res May 15 2014 20 (10) 2505-2507; DOI:10.1158/1078-0432.CCR-14-0370

Molecular Pathways

Molecular Pathways

Molecular Pathways: Preclinical Models and Clinical Trials with Metformin in Breast Cancer

Alastair M. Thompson

Clin Cancer Res May 15 2014 20 (10) 2508-2515; DOI:10.1158/1078-0432.CCR-13-0354
Molecular Pathways

Molecular Pathways: Adaptive Kinome Reprogramming in Response to Targeted Inhibition of the BRAF–MEK–ERK Pathway in Cancer

Gary L. Johnson, Timothy J. Stuhlmiller, Steven P. Angus, Jon S. Zawistowski and Lee M. Graves

Clin Cancer Res May 15 2014 20 (10) 2516-2522; DOI:10.1158/1078-0432.CCR-13-1081

CCR Focus

CCR Focus

The Language of Pharmacodynamics

Susan E. Bates

Clin Cancer Res May 15 2014 20 (10) 2524-2524; DOI:10.1158/1078-0432.CCR-14-0739
CCR Focus

Pharmacologic Biomarkers in the Development of Stratified Cancer Medicine

William Douglas Figg and David R. Newell

Clin Cancer Res May 15 2014 20 (10) 2525-2529; DOI:10.1158/1078-0432.CCR-14-0511
CCR Focus

Using Pharmacogene Polymorphism Panels to Detect Germline Pharmacodynamic Markers in Oncology

Daniel L. Hertz and Howard L. McLeod

Clin Cancer Res May 15 2014 20 (10) 2530-2540; DOI:10.1158/1078-0432.CCR-13-2780
CCR Focus

Genome-Wide Association Study: A Useful Tool to Identify Common Genetic Variants Associated with Drug Toxicity and Efficacy in Cancer Pharmacogenomics

Siew-Kee Low, Atsushi Takahashi, Taisei Mushiroda and Michiaki Kubo

Clin Cancer Res May 15 2014 20 (10) 2541-2552; DOI:10.1158/1078-0432.CCR-13-2755
CCR Focus

Circulating Tumor Cells: A Multifunctional Biomarker

Timothy A. Yap, David Lorente, Aurelius Omlin, David Olmos and Johann S. de Bono

Clin Cancer Res May 15 2014 20 (10) 2553-2568; DOI:10.1158/1078-0432.CCR-13-2664
CCR Focus

In Vivo Imaging as a Pharmacodynamic Marker

Astrid A.M. van der Veldt and Adriaan A. Lammertsma

Clin Cancer Res May 15 2014 20 (10) 2569-2577; DOI:10.1158/1078-0432.CCR-13-2666
CCR Focus

Implementation of Validated Pharmacodynamic Assays in Multiple Laboratories: Challenges, Successes, and Limitations

Robert Kinders, Kate Ferry-Galow, Lihua Wang, Apurva K. Srivastava, Jiuping (Jay) Ji and Ralph E. Parchment

Clin Cancer Res May 15 2014 20 (10) 2578-2586; DOI:10.1158/1078-0432.CCR-14-0476
CCR Focus

Pharmacodynamic Biomarkers: Falling Short of the Mark?

Justin F. Gainor, Dan L. Longo and Bruce A. Chabner

Clin Cancer Res May 15 2014 20 (10) 2587-2594; DOI:10.1158/1078-0432.CCR-13-3132

Human Cancer Biology

Human Cancer Biology

FOXM1 Promotes the Warburg Effect and Pancreatic Cancer Progression via Transactivation of LDHA Expression

Jiujie Cui, Min Shi, Dacheng Xie, Daoyan Wei, Zhiliang Jia, Shaojiang Zheng, Yong Gao, Suyun Huang and Keping Xie

Clin Cancer Res May 15 2014 20 (10) 2595-2606; DOI:10.1158/1078-0432.CCR-13-2407
Human Cancer Biology

Human Melanoma Metastases Demonstrate Nonstochastic Site-Specific Antigen Heterogeneity That Correlates with T-cell Infiltration

Edmund K. Bartlett, Patricia A. Fetsch, Armando C. Filie, Andrea Abati, Seth M. Steinberg, John R. Wunderlich, Donald E. White, Daniel J. Stephens, Francesco M. Marincola, Steven A. Rosenberg and Udai S. Kammula

Clin Cancer Res May 15 2014 20 (10) 2607-2616; DOI:10.1158/1078-0432.CCR-13-2690
Human Cancer Biology

miR-141 Is a Key Regulator of Renal Cell Carcinoma Proliferation and Metastasis by Controlling EphA2 Expression

Xuanyu Chen, Xuegang Wang, Anming Ruan, Weiwei Han, Yan Zhao, Xing Lu, Pei Xiao, Hangchuan Shi, Rong Wang, Li Chen, Shaoyong Chen, Quansheng Du, Hongmei Yang and Xiaoping Zhang

Clin Cancer Res May 15 2014 20 (10) 2617-2630; DOI:10.1158/1078-0432.CCR-13-3224
Human Cancer Biology | AuthorChoice

Regulation of Colorectal Carcinoma Stemness, Growth, and Metastasis by an miR-200c-Sox2–Negative Feedback Loop Mechanism

Yan-Xia Lu, Li Yuan, Xiao-Lei Xue, Min Zhou, Yan Liu, Chao Zhang, Jing-Ping Li, Lin Zheng, Min Hong and Xue-Nong Li

Clin Cancer Res May 15 2014 20 (10) 2631-2642; DOI:10.1158/1078-0432.CCR-13-2348
Human Cancer Biology

Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast Cancer

Julia A. Beaver, Danijela Jelovac, Sasidharan Balukrishna, Rory L. Cochran, Sarah Croessmann, Daniel J. Zabransky, Hong Yuen Wong, Patricia Valda Toro, Justin Cidado, Brian G. Blair, David Chu, Timothy Burns, Michaela J. Higgins, Vered Stearns, Lisa Jacobs, Mehran Habibi, Julie Lange, Paula J. Hurley, Josh Lauring, Dustin A. VanDenBerg, Jill Kessler, Stacie Jeter, Michael L. Samuels, Dianna Maar, Leslie Cope, Ashley Cimino-Mathews, Pedram Argani, Antonio C. Wolff and Ben Ho Park

Clin Cancer Res May 15 2014 20 (10) 2643-2650; DOI:10.1158/1078-0432.CCR-13-2933

Cancer Therapy: Preclinical

Cancer Therapy: Preclinical

Id1-Induced IGF-II and Its Autocrine/Endocrine Promotion of Esophageal Cancer Progression and Chemoresistance—Implications for IGF-II and IGF-IR–Targeted Therapy

Bin Li, Sai Wah Tsao, Kwok Wah Chan, Dale L. Ludwig, Ruslan Novosyadlyy, Yuk Yin Li, Qing Yu He and Annie L.M. Cheung

Clin Cancer Res May 15 2014 20 (10) 2651-2662; DOI:10.1158/1078-0432.CCR-13-2735
Cancer Therapy: Preclinical

COX-2–Independent Effects of Celecoxib Sensitize Lymphoma B Cells to TRAIL-Mediated Apoptosis

Anne-Sophie Gallouet, Marion Travert, Laurence Bresson-Bepoldin, Fabien Guilloton, Céline Pangault, Sylvie Caulet-Maugendre, Thierry Lamy, Karin Tarte and Thierry Guillaudeux

Clin Cancer Res May 15 2014 20 (10) 2663-2673; DOI:10.1158/1078-0432.CCR-13-2305
Cancer Therapy: Preclinical | AuthorChoice

Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth In Vitro and In Vivo

Yansheng Hao, Bjoern Chapuy, Stefano Monti, Heather H. Sun, Scott J. Rodig and Margaret A. Shipp

Clin Cancer Res May 15 2014 20 (10) 2674-2683; DOI:10.1158/1078-0432.CCR-13-3007
Cancer Therapy: Preclinical

Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells

Smita K. Nair, Gabriel De Leon, David Boczkowski, Robert Schmittling, Weihua Xie, Janet Staats, Rebecca Liu, Laura A. Johnson, Kent Weinhold, Gary E. Archer, John H. Sampson and Duane A. Mitchell

Clin Cancer Res May 15 2014 20 (10) 2684-2694; DOI:10.1158/1078-0432.CCR-13-3268
Cancer Therapy: Preclinical

Anti-VEGF Antibodies Mitigate the Development of Radiation Necrosis in Mouse Brain

Xiaoyu Jiang, John A. Engelbach, Liya Yuan, Jeremy Cates, Feng Gao, Robert E. Drzymala, Dennis E. Hallahan, Keith M. Rich, Robert E. Schmidt, Joseph J.H. Ackerman and Joel R. Garbow

Clin Cancer Res May 15 2014 20 (10) 2695-2702; DOI:10.1158/1078-0432.CCR-13-1941
Cancer Therapy: Preclinical

ABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy

Fan Lin, Mark C. de Gooijer, Eloy Moreno Roig, Levi C.M. Buil, Susan M. Christner, Jan H. Beumer, Thomas Würdinger, Jos H. Beijnen and Olaf van Tellingen

Clin Cancer Res May 15 2014 20 (10) 2703-2713; DOI:10.1158/1078-0432.CCR-14-0084
Cancer Therapy: Preclinical

Metformin Sensitizes EGFR-TKI–Resistant Human Lung Cancer Cells In Vitro and In Vivo through Inhibition of IL-6 Signaling and EMT Reversal

Li Li, Rui Han, Hualiang Xiao, Caiyu Lin, Yubo Wang, Hao Liu, Kunlin Li, Hengyi Chen, Fenfen Sun, Zhenzhou Yang, Jianxin Jiang and Yong He

Clin Cancer Res May 15 2014 20 (10) 2714-2726; DOI:10.1158/1078-0432.CCR-13-2613
Cancer Therapy: Preclinical

Profound Prevention of Experimental Brain Metastases of Breast Cancer by Temozolomide in an MGMT-Dependent Manner

Diane Palmieri, Renata Duchnowska, Stephan Woditschka, Emily Hua, Yongzhen Qian, Wojciech Biernat, Katarzyna Sosińska-Mielcarek, Brunilde Gril, Andreas M. Stark, Stephen M. Hewitt, David J. Liewehr, Seth M. Steinberg, Jacek Jassem and Patricia S. Steeg

Clin Cancer Res May 15 2014 20 (10) 2727-2739; DOI:10.1158/1078-0432.CCR-13-2588
Cancer Therapy: Preclinical

Biologic Effects of Platelet-Derived Growth Factor Receptor α Blockade in Uterine Cancer

Ju-Won Roh, Jie Huang, Wei Hu, XiaoYun Yang, Nicholas B. Jennings, Vasudha Sehgal, Bo Hwa Sohn, Hee Dong Han, Sun Joo Lee, Duangmani Thanapprapasr, Justin Bottsford-Miller, Behrouz Zand, Heather J. Dalton, Rebecca A. Previs, Ashley N. Davis, Koji Matsuo, Ju-Seog Lee, Prahlad Ram, Robert L. Coleman and Anil K. Sood

Clin Cancer Res May 15 2014 20 (10) 2740-2750; DOI:10.1158/1078-0432.CCR-13-2507

Imaging, Diagnosis, Prognosis

Imaging, Diagnosis, Prognosis

Repeatability of Quantitative FDG-PET/CT and Contrast-Enhanced CT in Recurrent Ovarian Carcinoma: Test–Retest Measurements for Tumor FDG Uptake, Diameter, and Volume

Andrea G. Rockall, Norbert Avril, Raymond Lam, Robert Iannone, P. David Mozley, Christine Parkinson, Donald Bergstrom, Evis Sala, Shah-Jalal Sarker, Iain A. McNeish and James D. Brenton

Clin Cancer Res May 15 2014 20 (10) 2751-2760; DOI:10.1158/1078-0432.CCR-13-2634
Imaging, Diagnosis, Prognosis

A Signature Predicting Poor Prognosis in Gastric and Ovarian Cancer Represents a Coordinated Macrophage and Stromal Response

Rita A. Busuttil, Joshy George, Richard W. Tothill, Kylie Ioculano, Adam Kowalczyk, Catherine Mitchell, Stephen Lade, Patrick Tan, Izhak Haviv and Alex Boussioutas

Clin Cancer Res May 15 2014 20 (10) 2761-2772; DOI:10.1158/1078-0432.CCR-13-3049
Imaging, Diagnosis, Prognosis

In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas

Kurt A. Schalper, Vamsidhar Velcheti, Daniel Carvajal, Hallie Wimberly, Jason Brown, Lajos Pusztai and David L. Rimm

Clin Cancer Res May 15 2014 20 (10) 2773-2782; DOI:10.1158/1078-0432.CCR-13-2702

Cancer Therapy: Clinical

Cancer Therapy: Clinical

Population Pharmacokinetics of Bevacizumab in Children with Osteosarcoma: Implications for Dosing

David C. Turner, Fariba Navid, Najat C. Daw, Shenghua Mao, Jianrong Wu, Victor M. Santana, Michael Neel, Bhaskar Rao, Jennifer Reikes Willert, David M. Loeb, K. Elaine Harstead, Stacy L. Throm, Burgess B. Freeman III and Clinton F. Stewart

Clin Cancer Res May 15 2014 20 (10) 2783-2792; DOI:10.1158/1078-0432.CCR-13-2364
Cancer Therapy: Clinical

A Pharmacodynamic/Pharmacokinetic Study of Ficlatuzumab in Patients with Advanced Solid Tumors and Liver Metastases

Josep Tabernero, Maria Elena Elez, Maria Herranz, Isabel Rico, Ludmila Prudkin, Jordi Andreu, Jose Mateos, Maria Josep Carreras, May Han, James Gifford, Marc Credi, Wei Yin, Shefali Agarwal, Philip Komarnitsky and Jose Baselga

Clin Cancer Res May 15 2014 20 (10) 2793-2804; DOI:10.1158/1078-0432.CCR-13-1837

Predictive Biomarkers and Personalized Medicine

Predictive Biomarkers and Personalized Medicine | AuthorChoice

Quantitative Measurements of Tumoral p95HER2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab: Independent Validation of the p95HER2 Clinical Cutoff

Renata Duchnowska, Jeff Sperinde, Ahmed Chenna, Mojgan Haddad, Agnes Paquet, Yolanda Lie, Jodi M. Weidler, Weidong Huang, John Winslow, Tomasz Jankowski, Bogumiła Czartoryska-Arłukowicz, Piotr J. Wysocki, Małgorzata Foszczyńska-Kłoda, Barbara Radecka, Maria M. Litwiniuk, Jolanta Żok, Michał Wiśniewski, Dorota Zuziak, Wojciech Biernat and Jacek Jassem

Clin Cancer Res May 15 2014 20 (10) 2805-2813; DOI:10.1158/1078-0432.CCR-13-2782

Main menu

User menu

Search

Table of Contents

Highlights

CCR Translations

Molecular Pathways

CCR Focus

Human Cancer Biology

Cancer Therapy: Preclinical

Imaging, Diagnosis, Prognosis

Cancer Therapy: Clinical

Predictive Biomarkers and Personalized Medicine

Issue Highlights

Jump to

Articles

Info for

About Clinical Cancer Research